Literature DB >> 3340289

Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.

R Hohlfeld1, M Michels, K Heininger, U Besinger, K V Toyka.   

Abstract

In this uncontrolled study, 104 patients with generalized myasthenia gravis treated with azathioprine for a median period of 29 months (range, 1 month to 12 years) were surveyed for possible adverse reactions. These occurred in 36 patients (35%) in the following order of frequency: hematologic (18%), gastrointestinal (13%), infectious diseases (13%), and elevation of liver enzymes (6%). No allergic skin reactions were observed. Azathioprine had to be discontinued temporarily in a total of 11 patients (11%) because of possible side effects. The cause of death in the nine patients who died during the period of observation (up to 12 years) was related to myasthenic crisis in two patients. In five patients, a malignant tumor was diagnosed (two carcinoma of the prostate, one ovarian carcinoma, one bronchial carcinoma, and one renal lymphoma) after 2.5 years, 6 months, 3 months, 5 years, and 6 years of treatment, respectively. A causal relationship seems unlikely in the first four cases, but cannot be excluded in the one case of late lymphoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3340289     DOI: 10.1212/wnl.38.2.258

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Primary CNS lymphoma in myasthenic on long-term azathioprine.

Authors:  Pasquale F Finelli
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

3.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

4.  Long term treatment of myasthenia gravis with azathioprine.

Authors:  V Fonseca; C W Havard
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

Review 5.  [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].

Authors:  F Kästner; W Paulus; M Deckert; P Schlegel; S Evers; I W Husstedt
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

Review 6.  Socio-economic aspects of neuroimmunological diseases.

Authors:  Peter Rieckmann
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

7.  Unsatisfactory outcomes in myasthenia gravis: influence by care providers.

Authors:  Murielle Dunand; Stephan A Botez; François-Xavier Borruat; Pascale Roux-Lombard; François Spertini; Thierry Kuntzer
Journal:  J Neurol       Date:  2009-09-17       Impact factor: 4.849

Review 8.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Christabelle M Chen; Harpal K Marway; Sean McKeag; Charles V J Mifsud; Andrew M Pilling; Matthew J Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

Review 10.  Ocular myasthenia gravis.

Authors:  G A March; L N Johnson
Journal:  J Natl Med Assoc       Date:  1993-09       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.